The influence of diabetes on Parkinson’s progression
In recent research funded by Cure Parkinson’s, scientists have provided the strongest evidence to date that diabetes can affect the progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death. The biotech company, Inhibikase, has been developing a drug which dampens down abnormal c-Abl protein.
New clinical trials targeting the LRRK2 gene
LRRK2 is a protein that becomes hyperactive in some people with Parkinson’s, and this is believed to be involved in the progression of their Parkinson’s.
Dr Simon Stott appointed Director of Research
Cure Parkinson’s is pleased to announce that Dr Simon Stott has been promoted to the role of Director of Research.
A million steps forward for Parkinson’s
On Tuesday 31 May, six friends from Hertfordshire crossed the finish line of their challenge of collectively walking a million steps in May, raising funds and awareness for Parkinson’s research.